< More articles


Al Qasimi Hospital Poised to Perform First Total Artificial Heart Implant in UAE

June 4, 2018

Syncardia Systems, LLC., a Picard Medical Company

Sharjah, United Arab Emirates — June 4, 2018 — Al Qasimi Hospital in the United Arab Emirates is poised to make history when its surgeons become the first in the country to implant the SynCardia temporary Total Artificial Heart (TAH). The device will be used as a treatment for patients suffering from end-stage heart failure affecting both sides of the heart (biventricular failure).

According to Dr. Arif Al Nooryani, CEO and head of cardiology at Al Qasimi, the SynCardia TAH will help save the lives of patients who would otherwise be out of options. “There are certain complexes for ‘global heart failure’ patients, one of which is waiting time, and sometimes it takes a year or even two years waiting for a suitable heart,” he explains. “These patients are the candidates for the Total Artificial Heart (TAH), which works as a ‘bridging strategy’ for those waiting for a donor heart.”

Dr. Al Nooryani believes the procedure will play a vital role in the fight against heart failure, especially as heart disease cases continue to rise globally. “This is a major disease,” he says. “We should help improve the quality of the patients’ lives. We shouldn’t keep this kind of technology away from them.”

The hospital plans to perform its first TAH implant this year.

Read the full story on the Khaleej Times.

About SynCardia Systems, LLC

Headquartered in Tucson, Ariz., SynCardia manufactures the world’s only commercially approved total artificial heart. In clinical use for more than 35 years and with more than 1,800 implants, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied TAH in the world.

By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement. When a donor heart isn’t an available option, SynCardia provides a new heart without the wait for patients with end-stage heart failure affecting both sides of the heart (biventricular failure).